A human-oriented design process for collaborative robotics

The potential of collaborative robotics often does not materialize in an efficient design of the human-robot collaboration. Technology-oriented approaches are no longer enough in the Industry 4.0 era. This work proposes a set of methods to support manufacturing engineers in the human-oriented design process of integrated production systems to obtain satisfactory performance in the mass customization paradigm, without impacting the safety and health of workers. It founds the design criteria definition on five main pillars (safety, ergonomics, effectiveness, flexibility, and costs), favors the consideration of different design alternatives, and leads their selection. The dynamic impact of the design choices on the various elements of the system prevails over the static design constraints. The method has been experimented in collaboration with the major kitchen manufacturer in Italy, which introduced a collaborative robotics cell in the drawers' assembly line. It resulted in a more balanced production line (10% more), a verified risk minimization (RULA score reduced from 5 to 3 and OCRA score from 13.30 to 5.70), and a greater allocation of operators to high added value activities

Tools and Methods for Human Robot Collaboration: Case Studies at i-LABS

The collaboration among humans and machines is one of the most relevant topics in the Industry 4.0 paradigm. Collaborative robotics owes part of the enormous impact it has had in small and medium size enterprises to its innate vocation for close cooperation between human operators and robots. The i-Labs laboratory, which is introduced in this paper, developed some case studies in this sense involving different technologies at different abstraction levels to analyse the feasibility of human-robot interaction in common, yet challenging, application scenarios. The ergonomics of the processes, safety of operators, as well as effectiveness of the cooperation are some of the aspects under investigation with the main objective of drawing to these issues the attention from industries who could benefit from them

Nivel de sospecha de enfermedad de Fabry en profesionales de la salud en el primer nivel de atención : Buenos Aires, mayo 2015

La enfermedad de Fabry es una enfermedad genética, hereditaria autosómica recesiva, de depósito lisosomal. Pertenece a los errores innatos del metabolismo. La incidencia varía de 1/40.000 a 1/117.000 nacidos vivos. Causa deficiencia total o parcial de la enzima alfa-galactosidasa A. Esta deficiencia interfiere en la degradación de globotriaosilceramida (Gb3), presente en muchos tipos de células, particularmente en las membranas de los eritrocitos. Los signos y síntomas sugestivos de E. de Fabry son: dolor intenso en manos y pies, dolor abdominal, angioqueratomas, opacidad corneal, facie tosca, proteinuria, entre otras. El compromiso vascular aumenta 12 veces el riego de ACV a partir de los 30 años, además de causar distintas afecciones cardíacas. La progresión del daño en el rinón evoluciona a insuficiencia renal crónica con necesidad de diálisis en la tercera década de la vida. Por todo lo expuesto es muy importante la detección temprana de esta enfermedad para instaurar un tratamiento adecuado con el objetivo de detener el deterioro de los órganos antes mencionados y reducir de esta forma la morbimortalidad de la Enfermedad de Fabry.Facultad de Ciencias Médica

Nivel de sospecha de enfermedad de Fabry en profesionales de la salud en el primer nivel de atención : Buenos Aires, mayo 2015

La enfermedad de Fabry es una enfermedad genética, hereditaria autosómica recesiva, de depósito lisosomal. Pertenece a los errores innatos del metabolismo. La incidencia varía de 1/40.000 a 1/117.000 nacidos vivos. Causa deficiencia total o parcial de la enzima alfa-galactosidasa A. Esta deficiencia interfiere en la degradación de globotriaosilceramida (Gb3), presente en muchos tipos de células, particularmente en las membranas de los eritrocitos. Los signos y síntomas sugestivos de E. de Fabry son: dolor intenso en manos y pies, dolor abdominal, angioqueratomas, opacidad corneal, facie tosca, proteinuria, entre otras. El compromiso vascular aumenta 12 veces el riego de ACV a partir de los 30 años, además de causar distintas afecciones cardíacas. La progresión del daño en el rinón evoluciona a insuficiencia renal crónica con necesidad de diálisis en la tercera década de la vida. Por todo lo expuesto es muy importante la detección temprana de esta enfermedad para instaurar un tratamiento adecuado con el objetivo de detener el deterioro de los órganos antes mencionados y reducir de esta forma la morbimortalidad de la Enfermedad de Fabry.Facultad de Ciencias Médica

Nivel de sospecha de enfermedad de Fabry en profesionales de la salud en el primer nivel de atención : Buenos Aires, mayo 2015

La enfermedad de Fabry es una enfermedad genética, hereditaria autosómica recesiva, de depósito lisosomal. Pertenece a los errores innatos del metabolismo. La incidencia varía de 1/40.000 a 1/117.000 nacidos vivos. Causa deficiencia total o parcial de la enzima alfa-galactosidasa A. Esta deficiencia interfiere en la degradación de globotriaosilceramida (Gb3), presente en muchos tipos de células, particularmente en las membranas de los eritrocitos. Los signos y síntomas sugestivos de E. de Fabry son: dolor intenso en manos y pies, dolor abdominal, angioqueratomas, opacidad corneal, facie tosca, proteinuria, entre otras. El compromiso vascular aumenta 12 veces el riego de ACV a partir de los 30 años, además de causar distintas afecciones cardíacas. La progresión del daño en el rinón evoluciona a insuficiencia renal crónica con necesidad de diálisis en la tercera década de la vida. Por todo lo expuesto es muy importante la detección temprana de esta enfermedad para instaurar un tratamiento adecuado con el objetivo de detener el deterioro de los órganos antes mencionados y reducir de esta forma la morbimortalidad de la Enfermedad de Fabry.Facultad de Ciencias Médica

Cobertura vacunal sarampión-rubéola en aspirantes al ingreso en el Instituto de Formación Superior IFSP 6001, La Plata año 2014

El sarampión (S) y la rubéola (R) son enfermedades inmunoprevenibles de reservorio humano exclusivo, pasibles de eliminación/erradicación. La vacunación para S se inició en nuestro país en el año 1971 a los 9 meses de edad; y, fue utilizada con diferentes esquemas. Objetivos: Identificar las coberturas de vacunación e implementar la vacunación con indicación personalizada para iniciar/completar esquemas.Facultad de Ciencias Médica

Cobertura vacunal sarampión-rubéola en aspirantes al ingreso en el Instituto de Formación Superior IFSP 6001, La Plata año 2014

El sarampión (S) y la rubéola (R) son enfermedades inmunoprevenibles de reservorio humano exclusivo, pasibles de eliminación/erradicación. La vacunación para S se inició en nuestro país en el año 1971 a los 9 meses de edad; y, fue utilizada con diferentes esquemas. Objetivos: Identificar las coberturas de vacunación e implementar la vacunación con indicación personalizada para iniciar/completar esquemas.Facultad de Ciencias Médica

Direct Access to 2,3,4,6-Tetrasubstituted Tetrahydro-2H-pyrans via Tandem SN2'-Prins Cyclization

A new direct and diastereoselective synthesis of activated 2,3,4,6-tetrasubstituted tetrahydro-2H-pyrans is described. In this reaction iron(III) catalyzed an SN2’-Prins cyclization tandem process leading to the creation of three new stereocenters in one single step. These activated tetrahydro-2H-pyran units are easily derivatizable through CuAAC conjugations in order to generate multi-functionalized complex molecules. DFT calculations support the in situ SN2’ reaction as a preliminary step in the Prins cyclizatio

Impact of chronic obstructive pulmonary disease on short-term outcome in patients with ST-elevation myocardial infarction during COVID-19 pandemic: insights from the international multicenter ISACS-STEMI registry

Background: Chronic obstructive pulmonary disease (COPD) is projected to become the third cause of mortality worldwide. COPD shares several pathophysiological mechanisms with cardiovascular disease, especially atherosclerosis. However, no definite answers are available on the prognostic role of COPD in the setting of ST elevation myocardial infarction (STEMI), especially during COVID-19 pandemic, among patients undergoing primary angioplasty, that is therefore the aim of the current study. Methods: In the ISACS-STEMI COVID-19 registry we included retrospectively patients with STEMI treated with primary percutaneous coronary intervention (PCI) between March and June of 2019 and 2020 from 109 high-volume primary PCI centers in 4 continents. Results: A total of 15,686 patients were included in this analysis. Of them, 810 (5.2%) subjects had a COPD diagnosis. They were more often elderly and with a more pronounced cardiovascular risk profile. No preminent procedural dissimilarities were noticed except for a lower proportion of dual antiplatelet therapy at discharge among COPD patients (98.9% vs. 98.1%, P = 0.038). With regards to short-term fatal outcomes, both in-hospital and 30-days mortality occurred more frequently among COPD patients, similarly in pre-COVID-19 and COVID-19 era. However, after adjustment for main baseline differences, COPD did not result as independent predictor for in-hospital death (adjusted OR [95% CI] = 0.913[0.658–1.266], P = 0.585) nor for 30-days mortality (adjusted OR [95% CI] = 0.850 [0.620–1.164], P = 0.310). No significant differences were detected in terms of SARS-CoV-2 positivity between the two groups. Conclusion: This is one of the largest studies investigating characteristics and outcome of COPD patients with STEMI undergoing primary angioplasty, especially during COVID pandemic. COPD was associated with significantly higher rates of in-hospital and 30-days mortality. However, this association disappeared after adjustment for baseline characteristics. Furthermore, COPD did not significantly affect SARS-CoV-2 positivity. Trial registration number: NCT 04412655 (2nd June 2020)

Gender Difference in the Effects of COVID-19 Pandemic on Mechanical Reperfusion and 30-Day Mortality for STEMI: Results of the ISACS-STEMI COVID-19 Registry

Background. Several reports have demonstrated the impact of the COVID-19 pandemic on the management and outcome of patients with ST-segment elevation myocardial infarction (STEMI). The aim of the current analysis is to investigate the potential gender difference in the effects of the COVID-19 pandemic on mechanical reperfusion and 30-day mortality for STEMI patients within the ISACS-STEMI COVID-19 Registry. Methods. This retrospective multicenter registry was performed in high-volume primary percutaneous coronary intervention (PPCI) centers on four continents and included STEMI patients undergoing PPCIs in March–June 2019 and 2020. Patients were divided according to gender. The main outcomes were the incidence and timing of the PPCI, (ischemia time ≥ 12 h and door-to-balloon ≥ 30 min) and in-hospital or 30-day mortality. Results. We included 16683 STEMI patients undergoing PPCIs in 109 centers. In 2020 during the pandemic, there was a significant reduction in PPCIs compared to 2019 (IRR 0.843 (95% CI: 0.825–0.861, p < 0.0001). We did not find a significant gender difference in the effects of the COVID-19 pandemic on the numbers of STEMI patients, which were similarly reduced from 2019 to 2020 in both groups, or in the mortality rates. Compared to prepandemia, 30-day mortality was significantly higher during the pandemic period among female (12.1% vs. 8.7%; adjusted HR [95% CI] = 1.66 [1.31–2.11], p < 0.001) but not male patients (5.8% vs. 6.7%; adjusted HR [95% CI] = 1.14 [0.96–1.34], p = 0.12). Conclusions. The COVID-19 pandemic had a significant impact on the treatment of patients with STEMI, with a 16% reduction in PPCI procedures similarly observed in both genders. Furthermore, we observed significantly increased in-hospital and 30-day mortality rates during the pandemic only among females. Trial registration number: NCT 04412655